
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is an immuno-pharma company with a potentially lucrative market opportunity for its flagship drugs Ampligen and Alferon N Injection in treating various cancers and viral diseases. With ongoing clinical trials and collaborations with larger companies like AstraZeneca, the company has strong growth prospects and potential catalysts for its stock. The recent focus on pancreatic cancer treatment and positive clinical data also add to the potential for high rewards, although there are still risks such as balance sheet and liquidity concerns, regulatory approvals, and competition to consider.
Bears say
AIM ImmunoTech is currently focusing on developing their flagship product, Ampligen, for the treatment of late-stage pancreatic cancer, which has shown success in safety and efficacy in clinical trials and has a large market with high mortality rates. The company expects to announce interim results from its various clinical trials in 2026/27, and with $6 million in cash and the recent raise of $6 million in stock, we believe they have enough cash to support their operations until late-2027. The company is located in Ocala, FL, and with upcoming clinical data from their trials, there is potential for positive catalysts for their stock.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares